Phase-2 Dacomitinib Study on Patients With EGFR-Driven Advanced Solid Tumours With Low EGFR-AS1 IncRNA Expr or Other Novel Emerging Biomarkers

NCT04946968 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Advanced Solid Tumours
Non-small Cell Lung Cancer
Head and Neck Squamous Cell Carcinoma

Interventions

DRUG: Oral Dacomitinib

Sponsor

National Cancer Centre, Singapore

Collaborators

[object Object]
[object Object]
[object Object]